Core Insights - The AON Global Healthcare Trend Report 2026 predicts a global average healthcare inflation rate of 9.8%, returning to single digits but still driven by factors such as increased healthcare service usage, technological advancements, rising private healthcare demand, and an aging population [10][11][12]. Global Overview - North America and Asia-Pacific are the only regions expected to see an increase in healthcare inflation rates, projected at 9.3% and 11.3% respectively, while other regions like Europe, Latin America, and the Middle East and Africa are experiencing a decline [13][15]. - The Middle East and Africa region has the highest inflation rate at 15.3%, despite a slight decrease from the previous year [15][16]. - The report emphasizes the importance of regional trends and the internal conditions driving inflation rate changes, as well as the strategies companies are adopting to mitigate rising costs [11][12]. Disease-Driven Costs - Cardiovascular diseases, cancer, and hypertension are identified as the top three drivers of healthcare costs, with musculoskeletal diseases entering the top five for the first time [19][20]. - GLP-1 medications, widely approved for diabetes treatment and weight loss, contribute approximately 10% to the healthcare trend growth rate, with some markets seeing contributions as high as 25% [24][25]. Corporate Strategies - Over 70% of multinational companies prioritize cost control in their benefits plans, employing strategies such as renegotiating with suppliers, initiating tenders, and implementing health promotion programs [17][33]. - Health benefits plans are the most common cost control measure, adopted by 86% of countries, while flexible benefits plans are gaining popularity due to their cost management and talent attraction advantages [35][36]. China-Specific Trends - China's healthcare inflation rate is projected at 7.8% for 2026, influenced by post-pandemic demand, aging population, and chronic disease prevalence [38][57]. - The report highlights the impact of healthcare reforms, including centralized procurement and DRG/DIP policies, on stabilizing costs in the long term [39][45]. - The increasing prevalence of chronic diseases and the aging population are expected to drive healthcare costs upward, despite short-term stabilization efforts [57][64]. Future Outlook - The report anticipates that healthcare costs will return to a normal upward trajectory due to factors such as chronic disease management pressures and the application of innovative drugs [56][57]. - The introduction of new drug categories in the national insurance and commercial health insurance systems is expected to enhance access to high-value treatments, although it may not significantly reduce costs [66].

智通财经APP获悉，美国银行周三宣布下调全球最大健康管理巨头联合健康集团(UNH.US)的股票评 级，预计这家医疗险企将因高管团队动荡被迫大幅修正2025年业绩预期。就在评级调整前夜，该公司股 价遭遇18%的罕见暴跌，创下2011年以来最大单日跌幅。 事件导火索源于周二盘后突发公告：掌舵多年的首席执行官安德鲁·威蒂突然宣布辞职，公司同时以"医 疗需求激增导致经营环境突变"为由，撤回此前发布的2025年财务指引。这一举动引发市场剧烈震荡， 次日股价重挫。 美国银行分析师乔安娜·加朱克在研报中指出，此次管理层地震直接打乱了联合健康的战略部署。她将 公司评级从"买入"降至"中性"，目标价从560美元大幅削减至350美元，降幅达37.5%。该分析师预计， 2025年联合健康的每股收益预期将较此前预测缩水10%-20%，若与最初制定的长期目标相比，下调幅度 更将高达21%-29%。 研报特别强调，撤销业绩指引的决定折射出两大深层隐忧：一是管理层对医疗费用上涨的持续性和覆盖 范围缺乏判断依据，二是需要为新任CEO预留充足时间重新制定战略规划。值得注意的是，联合健康在 电话会议中透露，正筹划在未来数月内制定新的竞标策略，目 ...